| abstract |
The present invention relates to the compounds of the formula (I) wherein R 1 is (A) or is phenyl, pyridinyl or pyridazinyl, wherein phenyl, pyridinyl and pyridazinyl can be optionally substituted by cyano, lower alkyl, halogen substituted phenyl , [1,2,4] oxadiazol-3-yl substituted by lower alkyl or by 2-oxo-piperidin-1-yl; X is NR or O; R is -C (O)-lower alkyl, -C (O) -cycloalkyl substituted by lower alkyl, cycloalkyl or is phenyl, pyridinyl or pyridazinyl, wherein phenyl, pyridinyl and pyridazinyl may be optionally substituted by lower alkyl, lower alkoxy, cyano, -C (O)-lower alkyl, halogen or lower alkyl substituted by halogen; R2 is hydrogen or lower alkyl; R3 is hydrogen, halogen, cyano, lower alkyl or lower alkyl substituted by halogen; R4 is hydrogen or lower alkyl; wherein R2 and are not simultaneously hydrogen or lower alkyl; R5 is lower alkyl; R6 is halogen, hydroxy, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, S (O) 2-lower alkyl or cyano; or to a pharmaceutically active acid addition salt thereof. The present compounds have been found to be high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder ( ADHD) |